Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTC004 with Cyclophosphamide and Fludarabine in Advanced Solid Tumors
NCT06277804Phase 1Not yet recruiting
- Sponsor
- Leto Laboratories
- Start
- Mar 2024
- Primary completion
- Jul 2027
- Modality
- Cytokines & Interferons
01
Overview
Phase 1, open-label trial of LTC004 in solid tumor and soft tissue sarcoma (STS) (2 arms), sponsored by Leto Laboratories. Primary endpoint: Safety, tolerability and antitumor efficacy of Combination at 12 months. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
LTC004
03
Conditions
solid tumorsoft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT06277804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06277804.